What were the price ranges for the PTGX CFO’s reported share sales?

The filing states the reported prices are weighted averages, with actual trades in ranges. One sale block ranged from $82.77 to $83.595 per share, and the other from $82.80 to $83.595, with full breakdowns available upon regulatory or shareholder request.

PTGX CFO exercises options, sells 46K shares

Protagonist Therapeutics Chief Financial Officer Asif Ali reported multiple stock transactions on January 27, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Financial Officer Asif Ali reported multiple stock transactions on January 27, 2026. He exercised stock options for 16,000 common shares at $19.19 and 12,000 shares at $12.17, then sold 28,000 shares at a weighted average price of $83.13 and 18,203 shares at $83.14. After these transactions, he directly owned 60,320 common shares. The exercised options relate to grants from April 18, 2022 and January 16, 2023, which vest over time subject to his continued service.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Ali Asif

Role Chief Financial Officer

Sold 46,203 shs ($3.84M)

Approx. gross sale proceeds $3.84M

Approx. exercise cost $453K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	16,000	$0.00	$0.00
Exercise	Stock Option (right to buy)	12,000	$0.00	$0.00
Exercise	Common Stock	16,000	$19.19	$307K
Exercise	Common Stock	12,000	$12.17	$146K
Sale	Common Stock	28,000	$83.13	$2.33M
Sale	Common Stock	18,203	$83.14	$1.51M

Holdings After Transaction: Stock Option (right to buy) — 69,347 contracts (Direct); Common Stock — 60,320 shares (Direct)

Footnotes (5)

F1. Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025.
F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
F5. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did PTGX CFO Asif Ali report on January 27, 2026?

Asif Ali reported exercising options and selling Protagonist Therapeutics shares on January 27, 2026. He exercised 28,000 options into common stock and sold 46,203 shares at weighted average prices around $83 per share, ending with 60,320 directly owned shares.

How many Protagonist Therapeutics (PTGX) shares did the CFO sell in this Form 4?

The CFO reported selling a total of 46,203 Protagonist Therapeutics common shares. These sales occurred in two blocks: 28,000 shares at a weighted average price of $83.13 and 18,203 shares at $83.14, executed through multiple trades within narrow price ranges.

What stock options did the PTGX CFO exercise in the reported transactions?

He exercised 16,000 options with a $19.19 exercise price and 12,000 options with a $12.17 exercise price. These options were originally granted in April 2022 and January 2023, with vesting tied to his continued service over multi-year schedules.

How many PTGX shares does the CFO own after these Form 4 transactions?

Following the reported exercises and sales, the CFO directly owns 60,320 Protagonist Therapeutics common shares. This figure includes shares previously held and reflects net ownership after converting options and selling a portion of his holdings on January 27, 2026.

How do the PTGX CFO’s option grants vest according to the Form 4 footnotes?

An April 18, 2022 option grant vested one quarter on April 18, 2023, with the remaining three quarters vesting in equal monthly installments through April 18, 2026. A January 16, 2023 grant vests in 48 equal monthly installments after the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/27/2026 - 09:20 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Asif

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

94560-1160

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/27/2026		M		16,000	A	$19.19	94,523⁽¹⁾	D
Common Stock	01/27/2026		M		12,000	A	$12.17	106,523	D
Common Stock	01/27/2026		S		28,000	D	$83.13⁽²⁾	78,523	D
Common Stock	01/27/2026		S		18,203	D	$83.14⁽³⁾	60,320	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$19.19	01/27/2026		M			16,000	⁽⁴⁾	04/18/2032	Common Stock	16,000	$0	50,800	D
Stock Option (right to buy)	$12.17	01/27/2026		M			12,000	⁽⁵⁾	01/15/2033	Common Stock	12,000	$0	18,547	D

Explanation of Responses:

1. Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

4. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.

5. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR